About us

Management and board of directors Peter Høngaard Andersen, Chairman of the board Peter Høngaard Andersen has extensive experience in drug discovery and development from companies such as Novo Nordisk and Lundbeck, where he last held the position as EVP and Head of Research and corporate patents. He is the founder of Innovation Fund Denmark and […]


Clinical phase I/II study with EDV2209 in SAH patients Edvince is preparing a phase I/II study in patients suffering from subarachnoid haemorrhage (SAH). The study is an interventional, double-blind, placebo-controlled, multiple-ascending dose first-in-human Phase I/II study in patients with subarachnoid hemorrhage. The primary objective is to investigate the safety and tolerability of the study drug […]

Contact us

Edvince AB Coegin Pharma AB c/o Medicon Village223 81 Lund, Sweden Tore Duvold, CEOM: +4561905066tore.duvold@gmail.com

Therapeutic area

Stroke More than 13 million people are hit by stroke each year. Globally, one in four people over the age of 25 will have a stroke in their lifetime. It is the second most common single cause of death in Europe, accounting for about 1 million deaths each year and it is the number one […]